Evaluating Blood Loss and the Effect of Antiplatelet Treatment in Foot and Ankle Amputations

David Schweer, Jonathon J. Carmouche, Daniel Jupiter, Timothy Ball, J. Randolph Clements

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The interrelationship between diabetes mellitus and cardiovascular disease is well-documented, and, secondary to the latter, is the use of antiplatelet therapy. Although diabetes and the associated vascular manifestations are driving forces behind lower extremity amputations, few data are available on the risks of perioperative antiplatelet therapy with foot and ankle amputations. The goal of the present study was to address the surgical effect of continuing or discontinuing antiplatelet therapy before foot and/or ankle amputation. The following data were retrospectively collected: blood loss, pre- and postoperative hematocrit and hemoglobin, operative time, amputation type, age, diabetic status, antiplatelet treatment, and number of transfusions during the perioperative period. Perioperative antiplatelet therapy was defined as exposure to aspirin or clopidogrel within 3 days before surgery. To compare the outcomes between groups, the following factors were analyzed using bivariate analyses and then multivariate regression models: (1) the need for transfusions, (2) high blood loss (>20 mL), (3) volume of blood loss, and (4) operative time. The noninferiority of continued antiplatelet use was assessed in terms of operative time and blood loss, using a noninferiority margin of 10 minutes or 10 mL, respectively. Antiplatelet therapy was not a statistically significant risk factor for any of the studied outcomes on multivariate analysis. Equivalence testing revealed that continuing antiplatelet therapy is not inferior to discontinuing perioperative therapy in terms of blood loss and operative time. Multivariate analysis of the data suggested that antiplatelet therapy has no statistically significant impact on blood loss, transfusion rate, or operative time.

Original languageEnglish (US)
Pages (from-to)1210-1215
Number of pages6
JournalJournal of Foot and Ankle Surgery
Volume55
Issue number6
DOIs
StatePublished - Nov 1 2016

Fingerprint

Amputation
Ankle
Operative Time
Therapeutics
Multivariate Analysis
clopidogrel
Foot
Postoperative Hemorrhage
Perioperative Period
Blood Volume
Hematocrit
Blood Transfusion
Aspirin
Blood Vessels
Lower Extremity
Diabetes Mellitus
Hemoglobins
Cardiovascular Diseases

Keywords

  • blood loss
  • clopidogrel
  • diabetes mellitus
  • hemorrhage
  • hemostasis
  • platelets

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Evaluating Blood Loss and the Effect of Antiplatelet Treatment in Foot and Ankle Amputations. / Schweer, David; Carmouche, Jonathon J.; Jupiter, Daniel; Ball, Timothy; Clements, J. Randolph.

In: Journal of Foot and Ankle Surgery, Vol. 55, No. 6, 01.11.2016, p. 1210-1215.

Research output: Contribution to journalArticle

Schweer, David ; Carmouche, Jonathon J. ; Jupiter, Daniel ; Ball, Timothy ; Clements, J. Randolph. / Evaluating Blood Loss and the Effect of Antiplatelet Treatment in Foot and Ankle Amputations. In: Journal of Foot and Ankle Surgery. 2016 ; Vol. 55, No. 6. pp. 1210-1215.
@article{d648472301d64bc399ed1c98c9221f52,
title = "Evaluating Blood Loss and the Effect of Antiplatelet Treatment in Foot and Ankle Amputations",
abstract = "The interrelationship between diabetes mellitus and cardiovascular disease is well-documented, and, secondary to the latter, is the use of antiplatelet therapy. Although diabetes and the associated vascular manifestations are driving forces behind lower extremity amputations, few data are available on the risks of perioperative antiplatelet therapy with foot and ankle amputations. The goal of the present study was to address the surgical effect of continuing or discontinuing antiplatelet therapy before foot and/or ankle amputation. The following data were retrospectively collected: blood loss, pre- and postoperative hematocrit and hemoglobin, operative time, amputation type, age, diabetic status, antiplatelet treatment, and number of transfusions during the perioperative period. Perioperative antiplatelet therapy was defined as exposure to aspirin or clopidogrel within 3 days before surgery. To compare the outcomes between groups, the following factors were analyzed using bivariate analyses and then multivariate regression models: (1) the need for transfusions, (2) high blood loss (>20 mL), (3) volume of blood loss, and (4) operative time. The noninferiority of continued antiplatelet use was assessed in terms of operative time and blood loss, using a noninferiority margin of 10 minutes or 10 mL, respectively. Antiplatelet therapy was not a statistically significant risk factor for any of the studied outcomes on multivariate analysis. Equivalence testing revealed that continuing antiplatelet therapy is not inferior to discontinuing perioperative therapy in terms of blood loss and operative time. Multivariate analysis of the data suggested that antiplatelet therapy has no statistically significant impact on blood loss, transfusion rate, or operative time.",
keywords = "blood loss, clopidogrel, diabetes mellitus, hemorrhage, hemostasis, platelets",
author = "David Schweer and Carmouche, {Jonathon J.} and Daniel Jupiter and Timothy Ball and Clements, {J. Randolph}",
year = "2016",
month = "11",
day = "1",
doi = "10.1053/j.jfas.2016.07.018",
language = "English (US)",
volume = "55",
pages = "1210--1215",
journal = "Journal of Foot and Ankle Surgery",
issn = "1067-2516",
publisher = "Academic Press Inc.",
number = "6",

}

TY - JOUR

T1 - Evaluating Blood Loss and the Effect of Antiplatelet Treatment in Foot and Ankle Amputations

AU - Schweer, David

AU - Carmouche, Jonathon J.

AU - Jupiter, Daniel

AU - Ball, Timothy

AU - Clements, J. Randolph

PY - 2016/11/1

Y1 - 2016/11/1

N2 - The interrelationship between diabetes mellitus and cardiovascular disease is well-documented, and, secondary to the latter, is the use of antiplatelet therapy. Although diabetes and the associated vascular manifestations are driving forces behind lower extremity amputations, few data are available on the risks of perioperative antiplatelet therapy with foot and ankle amputations. The goal of the present study was to address the surgical effect of continuing or discontinuing antiplatelet therapy before foot and/or ankle amputation. The following data were retrospectively collected: blood loss, pre- and postoperative hematocrit and hemoglobin, operative time, amputation type, age, diabetic status, antiplatelet treatment, and number of transfusions during the perioperative period. Perioperative antiplatelet therapy was defined as exposure to aspirin or clopidogrel within 3 days before surgery. To compare the outcomes between groups, the following factors were analyzed using bivariate analyses and then multivariate regression models: (1) the need for transfusions, (2) high blood loss (>20 mL), (3) volume of blood loss, and (4) operative time. The noninferiority of continued antiplatelet use was assessed in terms of operative time and blood loss, using a noninferiority margin of 10 minutes or 10 mL, respectively. Antiplatelet therapy was not a statistically significant risk factor for any of the studied outcomes on multivariate analysis. Equivalence testing revealed that continuing antiplatelet therapy is not inferior to discontinuing perioperative therapy in terms of blood loss and operative time. Multivariate analysis of the data suggested that antiplatelet therapy has no statistically significant impact on blood loss, transfusion rate, or operative time.

AB - The interrelationship between diabetes mellitus and cardiovascular disease is well-documented, and, secondary to the latter, is the use of antiplatelet therapy. Although diabetes and the associated vascular manifestations are driving forces behind lower extremity amputations, few data are available on the risks of perioperative antiplatelet therapy with foot and ankle amputations. The goal of the present study was to address the surgical effect of continuing or discontinuing antiplatelet therapy before foot and/or ankle amputation. The following data were retrospectively collected: blood loss, pre- and postoperative hematocrit and hemoglobin, operative time, amputation type, age, diabetic status, antiplatelet treatment, and number of transfusions during the perioperative period. Perioperative antiplatelet therapy was defined as exposure to aspirin or clopidogrel within 3 days before surgery. To compare the outcomes between groups, the following factors were analyzed using bivariate analyses and then multivariate regression models: (1) the need for transfusions, (2) high blood loss (>20 mL), (3) volume of blood loss, and (4) operative time. The noninferiority of continued antiplatelet use was assessed in terms of operative time and blood loss, using a noninferiority margin of 10 minutes or 10 mL, respectively. Antiplatelet therapy was not a statistically significant risk factor for any of the studied outcomes on multivariate analysis. Equivalence testing revealed that continuing antiplatelet therapy is not inferior to discontinuing perioperative therapy in terms of blood loss and operative time. Multivariate analysis of the data suggested that antiplatelet therapy has no statistically significant impact on blood loss, transfusion rate, or operative time.

KW - blood loss

KW - clopidogrel

KW - diabetes mellitus

KW - hemorrhage

KW - hemostasis

KW - platelets

UR - http://www.scopus.com/inward/record.url?scp=84994745277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994745277&partnerID=8YFLogxK

U2 - 10.1053/j.jfas.2016.07.018

DO - 10.1053/j.jfas.2016.07.018

M3 - Article

VL - 55

SP - 1210

EP - 1215

JO - Journal of Foot and Ankle Surgery

JF - Journal of Foot and Ankle Surgery

SN - 1067-2516

IS - 6

ER -